Pharmacogenomics-based clinical trial design recommendation and management system and method

• US 20030108938A1
• Filed: 11/06/2002
• Published: 06/12/2003
• Est. Priority Date: 11/06/2001
• Status: Abandoned Application

• Current Assignee: David Pickar, Elizabeth Gray, Jack D. Hidary
• Original Assignee: David Pickar, Elizabeth Gray, Jack D. Hidary
• Inventors: Gray, Elizabeth, Hidary, Jack D., Pickar, David
• Application Number:
  US10/288,336
• Publication Number:
  US 20030108938A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: G16H 10/20 for electronic clinical trials or questionnaires
• CPC Class Codes: G16H 10/60 for patient-specific data, e.g. for electronic patient records
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 50/30 for calculating health indices; for individual health risk assessment
• CPC Class Codes: G16H 70/40 relating to drugs, e.g. their side effects or intended usage

Abstract

The present invention relates to computer systems and methods for clinical trials for linking biological information including genomic and proteomic information to the conduct and success of the clinical trial process for therapeutic agents. In particular, the present invention relates to computer systems and methods of analyzing genotypes, clinical phenotypes, and clinical trial requirements for providing recommendations for conduct of various phases of clinical trial process. The system may include a genotype database, a clinical database, clinical trial requirements database, an analytical computer, a recommended trial database, a blood bank, and sequencing machines.

Claims

1. A pharmacogenomic system for clinical trials, the system comprising:

a genotype database (GDB), the GDB comprising genetic information for a plurality of patients;

a clinical database (CDB), the CDB comprising clinical phenotypic information for a plurality of patients;

a clinical trial requirement database (CRDB), the CRDB comprising information on clinical trial requirements for at least one phase of a clinical trial;

association modules that are connected to GDB, and CDB and are adopted to determine an association between the genetic information and the clinical phenotypic information for a plurality of patients; and

recommendation modules that are connected to GDB, CDB, and CRDB and adopted to provide clinical trial recommendations utilizing the genetic information, the clinical phenotypic information, the clinical trial requirement information and the determined association between the clinical information and the genetic information.

2. The system of claim 1 further comprising selection modules that are connected to the system for selecting one or more patients based on the genetic information, wherein the selection is performed using plurality of statistical methods.

3. The system of claim 1, wherein the genetic information correspond to one or more variation in candidate genes.

4. The system of claim 1, wherein the genetic information correspond to plurality of Single Nucleotide Polymorphisms.

5. The system of claim 1, wherein the clinical trial requirement information correspond to one or more protocols for Phase I of a clinical trial.

6. The system of claim 1, wherein the clinical trial requirement information correspond to one or more inclusion/exclusion criteria for clinical trials.

7. The system of claim 1, wherein the association is determined my one or more of pre-determined statistical methods.

8. The system of claim 1, wherein the recommendation modules perform optimization of clinical trial parameters for providing clinical trial recommendations.

9. A pharmacogenomic system for clinical trials, the system comprising:

a genotype database (GDB), the GDB comprising genetic information for a plurality of patients;

a clinical database (CDB), the CDB comprising clinical phenotypic information for a plurality of patients;

a clinical trial requirement database (CRDB), the CRDB comprising information on clinical trial requirements for at least one phase of a clinical trial;

association means that are connected to GDB, and CDB and are adopted to determine an association between the genetic information and the clinical phenotypic information for a plurality of patients; and

recommendation means that are connected to GDB, CDB, and CRDB and adopted to provide clinical trial recommendations utilizing the genetic information, the clinical phenotypic information, the clinical trial requirement information and the determined association between the clinical information and the genetic information.

10. The system of claim 9 further comprising selection means for selecting one or more patients based on the genetic information, wherein the selection is performed using plurality of statistical methods.

11. The system of claim 9, wherein the genetic information correspond to one or more variation in candidate genes.

12. The system of claim 9, wherein the genetic information correspond to plurality of Single Nucleotide Polymorphisms.

13. The system of claim 9, wherein the clinical trial requirement information correspond to one or more protocols for Phase I of a clinical trial.

14. The system of claim 9, wherein the clinical trial requirement information correspond to one or more inclusion/exclusion criteria for clinical trials.

15. The system of claim 9, wherein the association is determined my one or more of pre-determined statistical methods.

16. The system of claim 9, wherein the recommendation means perform optimization of clinical trial parameters for providing clinical trial recommendations.

17. A pharmacogenomic method for clinical trials, the method comprising the steps of:

enabling a user to access a genotype database (GDB), the GDB comprising genetic information for a plurality of patients;

enabling a user to access a clinical database (CDB), the CDB comprising clinical phenotypic information for a plurality of patients;

enabling a user to access a clinical trial requirement database (CRDB), the CRDB comprising information on clinical trial requirements for at least one phase of a clinical trial;

enabling a user to determine an association between the genetic information and the clinical phenotypic information for a plurality of patients; and

enabling a user to cause the system to provide clinical trial recommendations utilizing the genetic information, the clinical phenotypic information, the clinical trial requirement information and the determined association between the clinical information and the genetic information.

18. The method of claim 17 further comprising a step of enabling a user to select one or more patients based on the genetic information, wherein the selection is performed using plurality of statistical methods.

19. The method of claim 17, wherein the genetic information correspond to one or more variation in candidate genes.

20. The method of claim 17, wherein the genetic information correspond to plurality of Single Nucleotide Polymorphisms.

21. The method of claim 17, wherein the clinical trial requirement information correspond to one or more protocols for Phase I of a clinical trial.

22. The method of claim 17, wherein the clinical trial requirement information correspond to one or more inclusion/exclusion criteria for clinical trials.

23. The method of claim 17, wherein the association is determined my one or more of predetermined statistical methods.

24. The method of claim 17, wherein method performs optimization of clinical trial parameters for providing clinical trial recommendations.

25. A processor readable pharmacogenomic medium for clinical trials, said processor readable medium comprising:

a first processor readable program code for enabling a user to access a genotype database (GDB), the GDB comprising genetic information for a plurality of patients;

a second processor readable program code for enabling a user to access a clinical database (CDB), the CDB comprising clinical phenotypic information for a plurality of patients;

a third processor readable program code for enabling a user to access a clinical trial requirement database (CRDB), the CRDB comprising information on clinical trial requirements for at least one phase of a clinical trial;

a fourth processor readable program code for enabling a user to determine an association between the genetic information and the clinical phenotypic information for a plurality of patients; and

a fifth processor readable program code for enabling a user to cause the system to provide clinical trial recommendations utilizing the genetic information, the clinical phenotypic information, the clinical trial requirement information and the determined association between the clinical information and the genetic information.

26. A pharmacogenomic system for clinical trials, the system comprising:

means for providing genetic information for a plurality of patients;

means for providing clinical phenotypic information for a plurality of patients;

means for providing information on clinical trial requirements for at least one phase of a clinical trial;

association modules that determine an association between the genetic information and the clinical phenotypic information for a plurality of patients; and

recommendation modules that provide clinical trial recommendations utilizing the genetic information, the clinical phenotypic information, the clinical trial requirement information and the determined association between the clinical information and the genetic information.